Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL30548559 | 0.90 | LMNA (0.44) | LMNASMN1; SMN2GAACHRNB2CHRNA4 | |
| SCHEMBL26626619 | 0.89 | GRM3 (0.48) | LMNASMN1; SMN2CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL1420981 | 0.89 | GRM3 (0.48) | LMNASMN1; SMN2CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL26626591 | 0.89 | GRM3 (0.48) | LMNASMN1; SMN2CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL3498368 | 0.88 | LMNA (0.55) | LMNASMN1; SMN2GAANPC1RAB9A | |
| SCHEMBL14009871 | 0.85 | SMN1; SMN2 (0.46) | SMN1; SMN2GAACHRNB2CHRNA4CHRNB4 | |
| SCHEMBL9675197 | 0.85 | SMN1; SMN2 (0.59) | SMN1; SMN2GAACHRNB2CHRNA4CHRNB4 | |
| SCHEMBL3231020 | 0.84 | CHRNB2 (0.53) | LMNASMN1; SMN2GAACHRNB2CHRNA4 | |
| SCHEMBL24159167 | 0.83 | GAA (0.54) | LMNASMN1; SMN2GAAALDH1A1 | |
| SCHEMBL9214032 | 0.81 | GAA (0.62) | SMN1; SMN2GAANPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260008789-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-20240173267-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | ONCORUS, INC. (US) | 2024-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260008789-A1 | KRAS MODULATORS AND USES THEREOF | KRAS, NRAS, HRAS | LMNA 3054/4885SMN1; SMN2 545/4885GAA 3952/4885 |
| US-20240173267-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | POLRMT, POLN, NSUN2 | LMNA 303/4885SMN1; SMN2 295/4885GAA 917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.